Cutaneous squamous cell carcinoma and basal cell carcinoma account for 99% of all cases of non-melanocytic skin cancer (NMSC). Based on an increasing understanding of the pathomechanisms that play a role in tumor development, progression and differentiation, innovative therapeutic strategies are currently being tested in studies. These include therapeutic approaches to promote anti-tumor immunity by targeting newly identified target structures.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Cellular and Systemic Iron Homeostasis
“Steady State” – a delicately balanced equilibrium
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D